NCT02880163招募中不适用
Reducing Exsanguination Via In-Vivo Expandable Foam
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Change in systolic blood pressure after deployment of ResQFoam over baseline value
研究概览
简要总结
The purpose of this study is to demonstrate safety, effectiveness and benefit-risk profile of ResQFoam for the inhospital treatment of exsanguinating, intraabdominal haemorrhage due to trauma in patients where emergent laparotomy is required.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Estimated age of 15 years or older (or subject weight estimated at greater than 50 kg if age is unknown)
- •Emergent, exsanguinating hemorrhage, from abdominal source as defined by:
- •Class III or IV hemorrhagic shock or
- •Assessment of Blood Consumption (ABC) score ≥ 2
- •Confirmation of abdominal hemorrhage by:
- •Direct visualization or
- •Positive Focused Assessment with Sonography in Trauma (FAST) or
- •Diagnostic Peritoneal Aspiration (DPA)
- •No other known, uncontrolled active sources of hemorrhage
- •Subject is intubated and sedated per local guidelines
- •Decision to administer foam is made within 30 minutes of admission to the emergency department.
- •Decision made to proceed to emergent laparotomy made within 30 minutes of admission to the emergency department.
- •Definitive surgical care is expected to occur within three hours of foam deployment
- •Subject must also be receiving concurrent transfusion of fluids or blood products.
排除标准
- •Known or suspected major diaphragm injury
- •Known or suspected untreated pneumothorax
- •Known or suspected untreated hemothorax
- •Known or suspected blunt or penetrating cardiac or thoracic aortic trauma
- •Traumatic brain injury resulting in decapitation, visible brain matter or considered non- survivable based on initial physical exam
- •Received greater than five consecutive minutes of cardiopulmonary resuscitation in the pre-emergency department setting
- •Patients with Pulseless Electrical Activity
- •Known allergy to isocyanate
- •Known or suspected pregnancy
- •History of prior abdominal surgery or evidence of abdominal surgery (scars)
- •Disrupted abdominal wall that, in the opinion of the investigator would preclude ResQFoam from being adequately contained within the abdominal cavity
- •Subject in whom the abdominal aortic junctional tourniquet (AAJT) or Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) techniques have been used
- •Known Prisoners
- •Subjects with burns > 20% of total body surface area
- •Subject/legally authorized representative/subject family member purposefully opted out of participation in the study
- •Known Do Not Resuscitate order (DNR) or Physician Orders for Life Sustaining Treatment (POLST)
- •Known enrollment in another randomized, interventional study
结局指标
主要结局
Change in systolic blood pressure after deployment of ResQFoam over baseline value
时间窗: All SBP assessments prior to deployment of IP through removal of IP and completion of laparotomy. Patient will be followed through hospital discharge or through Day 30, whichever comes first.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Study Evaluating rFIX; BeneFIX® in Hemophilia BHemophilia BNCT00093171Wyeth is now a wholly owned subsidiary of Pfizer23
已完成
4 期
Study Evaluating ReFacto® in Hemophilia A Undergoing Major SurgeryHemophilia ANCT00092976Wyeth is now a wholly owned subsidiary of Pfizer15
终止
不适用
Goal-directed Fluid Resuscitation in Acute PancreatitisAcute PancreatitisNCT00853515Brigham and Women's Hospital40
已完成
不适用
Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling DeviceTraumatic Brain InjuryNCT02420639Advanced Cooling Therapy, Inc., d/b/a Attune Medical12
进行中（未招募）
不适用
Safety and Efficacy Study of the Xoft® Axxent® eBx® IORT System®Invasive Ductal CarcinomaDuctal Carcinoma in SituNCT01644669Xoft, Inc.1,200